US › Healthcare

Corvus Pharmaceuticals Inc (CRVS)

US · Healthcare · Biotechnology

$13.92+4.11%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-13.7M
Profit YoY
-190.1%
EPS
$-0.15
EPS estimate
$-0.15

EPS came in at -0.15 against a street estimate of -0.15 — a beat of 0.0%.

Key statistics

Market cap
$1.12B
Forward P/E
0.0
P/B
4.63
Book value
$2.86
EPS (TTM)
$-0.55
52-week high
$26.95
52-week low
$4.05
50-day MA
$13.26
200-day MA
$12.96
Beta
0.82

Analyst view

Analysts rate Corvus Pharmaceuticals Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $33.14.

Shareholding

Insiders
3.51%
Institutions
85.68%

Largest institutional holders

FundStake
Orbimed Advisors, LLC8.52%
BlackRock Inc7.33%
State Street Corp4.24%
Adams Street Partners LLC3.90%
Vanguard Capital Management, LLC3.85%
T. Rowe Price Associates, Inc.3.47%
Vivo Capital, LLC3.34%
Morgan Stanley - Brokerage Accounts2.97%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Corvus Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.